CALC — CalciMedica, Inc.

Open full analysis

Chart, dilution, float and news for CALC in the TickerWise workspace.

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 14
• Website: https://www.calcimedica.com

Latest SEC filings for CALC

• 2026-09-30424B5
• 2026-09-23S-8
• 2026-08-25SCHEDULE 13G
• 2026-08-24SCHEDULE 13D/A
• 2026-08-208-K
• 2026-08-118-K
• 2026-08-1110-Q
• 2026-07-24S-3
• 2026-07-24S-3
• 2026-07-23ARS

Open full analysis

Educational tool only — not investment advice.